

Application No. 09/645,590
Amdt. Dated Sept. 2, 2003
Reply to Office Action of June 3, 2003

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1. (currently amended) A method for [reducing the overproduction of] modulating an overactive neuropeptide Y (NPY) system in an individual, said method [being aimed to modulate] comprising the administration of an agent that modulates an overactive NPY system in said individual in an amount effective to modulate the NPY system, wherein the overactive NPY system results from an overproduction of NPY [is] caused by a polymorphism comprising the substitution of the position 7 leucine [for]by proline in the signal peptide part of the human preproNPY.

2. (currently amended) The method according to claim 1 wherein the overproduction of NPY is counteracted by administering [an antagonist] to said individual an antagonist that antagonizes the overproduction of NPY.

3. (withdrawn) The method according to claim 2 wherein said antagonist is aimed to decrease the expression of the NPY gene.

4. (original) The method according to claim 2 wherein said antagonist is an NPY receptor antagonist.

5. (withdrawn) The method according to claim 2 wherein said antagonist is an NPY antibody.

6. (withdrawn) The method according to claim 5 wherein said antibody is an antibody reacting with the NPY in serum.

7. (Canceled).

8. (withdrawn) The method according to claim 1, wherein the overproduction of NPY is caused by a polymorphism comprising the substitution of the position 7 leucine for proline in the signal peptide part of the human preproNPY, and wherein said individual is subjected to a method aimed to reduce or prevent expression of the mutated allele causing said polymorphism.

9. (withdrawn) The method according to claim 8, wherein said method is a specific gene therapy aimed to repair the mutated allele.

10. (withdrawn) The method according to claim 9 which comprises the use of an antisense oligonucleotide.

11. (withdrawn) The method according to claim 9 which comprises the use of a peptide nucleic acid (PNA).

12. (withdrawn) The method according to claim 9 which comprises the use of a ribozyme.

13. (withdrawn) The method according to claim 3 wherein the overproduction of NPY is caused by a polymorphism comprising the substitution of the position 7 leucine for proline in the signal peptide part of the human preproNPY.

14. (canceled).

Application No. 09/645,590
Amdt. Dated Sept. 2, 2003
Reply to Office Action of June 3, 2003

15. (withdrawn) The method according to claim 5 wherein the overproduction of NPY is caused by a polymorphism comprising the substitution of the position 7 leucine for proline in the signal peptide part of the human preproNPY.

16. (Withdrawn). The method according to claim 6 wherein the overproduction of NPY is caused by a polymorphism comprising the substitution of the position 7 leucine for proline in the signal peptide part of the human preproNPY.